SCHEMBL285337

SCHEMBL285337

CCC(C#N)c1ccsc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.39
ALOX5 P09917 1/20 0.38
MAPT P10636 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HIF1A Q16665 1/20 0.37
DRD2 P14416 1/20 0.33
DRD3 P35462 1/20 0.33
NEK1 Q96PY6 1/20 0.33
ESR1 P03372 4/20 0.33
ESR2 Q92731 4/20 0.33
IDO1 P14902 1/20 0.33
TDO2 P48775 1/20 0.33
CHRNB2 P17787 1/20 0.32
CHRNB4 P30926 1/20 0.32
CHRNA3 P32297 1/20 0.32
CHRNA4 P43681 1/20 0.32
CYP3A4 P08684 2/20 0.31
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP1A2 P05177 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL27543765 0.84 CCR1 (0.42) CCR1ALOX5MAPTSMN1; SMN2HIF1A
Bromide SCHEMBL27340514 0.84 CCR1 (0.42) CCR1ALOX5MAPTSMN1; SMN2HIF1A
SCHEMBL7508407 0.75
SCHEMBL20963155 0.74 ALOX5 (0.36) ALOX5MAPTSMN1; SMN2HIF1ADRD2
SCHEMBL12462086 0.74 ALOX5 (0.36) ALOX5MAPTSMN1; SMN2HIF1ADRD2
SCHEMBL9324461 0.74 CXCR1 (0.34) ALOX5MAPTSMN1; SMN2HIF1ACYP3A4
SCHEMBL11198210 0.74 CCR1 (0.40) CCR1ALOX5MAPTSMN1; SMN2HIF1A
SCHEMBL6494251 0.74
SCHEMBL12464829 0.73 ALOX5 (0.39) ALOX5DRD2DRD3ESR1ESR2
Hydrochloric Acid SCHEMBL7744173 0.72 IDO1 (0.42) CCR1ALOX5MAPTSMN1; SMN2HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541445-B2 Pyrazolopyridines VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-09-24 US disclosed
US-8541445-B2 Pyrazolopyridines VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-09-24 US disclosed
US-8541445-B2 Pyrazolopyridines VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-09-24 US disclosed
US-20120178778-A1 PYRAZOLOPYRIDINES VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-12 US disclosed
US-20120178778-A1 PYRAZOLOPYRIDINES VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-12 US disclosed
US-20120178778-A1 PYRAZOLOPYRIDINES VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-12 US disclosed
CN-102459259-A Pyrazolopyridines VERTEX PHARMA 2012-05-16 CN disclosed
EP-2427464-A1 PYRAZOLOPYRIDINES Vertex Pharmaceuticals Incorporated (US) 2012-03-14 EP disclosed
WO-2010129668-A1 PYRAZOLOPYRIDINES VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-11-11 WO disclosed
CN-101143867-A Antidepressant indolealkyl derivatves of heterocyclefused benzodioxan methylamines WYETH CORP (US) 2008-03-19 CN disclosed
CN-100358898-C Antidepressant indolealkyl derivatives of heterocycle-fused benzodi * alkylmethylamines WYETH CORP (US) 2008-01-02 CN disclosed
CN-1701075-A Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines WYETH CORP (US) 2005-11-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178778-A1 PYRAZOLOPYRIDINES MAP3K5, MAP4K5, MAP3K20 CCR1 3845/4885ALOX5 3849/4885MAPT 1153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.